PureTech Health (GB:PRTC) has released an update.
At PureTech Health’s Annual General Meeting, all proposed resolutions were approved by shareholders, including the election of new directors and the reappointment of PricewaterhouseCoopers LLP as auditors. Notably, there was over 20% opposition on resolutions concerning directors’ remuneration, prompting the board to commit to further shareholder engagement. PureTech Health, a clinical-stage biotherapeutics company, continues to focus on advancing its pipeline of therapeutics, with two approved by the FDA and the European Union and another filed for FDA approval.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
